TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03791710
Drug: Topical Cream
Normalized name: Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: serial dressing with topical agents e.g Silver Sulphadiazine
Study: NCT01207765
Drug: 90Y Zevalin
Normalized name: Zevalin KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will receive a single therapeutic dose of 90Y Zevalin at a dose of 0.4 mCi/kg, capped at a maximum dose of 32 mCi. 90Y Zevalin will be administered intravenously as a slow IV push over 10 minutes. 90Y Zevalin may be directly infused by stopping the flow from the IV bag and injecting the radiolabeled antibody directly into the IV line. A 0.22 micron filter must be on line between the syringe and the infusion port. The line must be flushed with at least 10cc normal saline after 90Y Zevalin has been infused.
Study: NCT03322735
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide 0.6-0.8g/m2/day IV for 2 days
Study: NCT04500418
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optically identical pills without CVC.
Study: NCT01468818
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
Study: NCT02535871
Drug: IDP-121 Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational Product: IDP-121 Lotion
Study: NCT02535871
Drug: IDP-121 Vehicle Lotion
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator Product: IDP-121 Vehicle Lotion
Study: NCT01838668
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two placebo capsules orally BID
Study: NCT04040023
Drug: Iron and vitamin Deficiencies Correction Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative:~For patient with iron deficiency: Intravenous iron supplementation For patient with folic acid or vitamin B12 deficiency : oral vitamin supplementation For patient with anemia: pre operative erythropoietin injections~Postoperative:~Systematic iron supplementation
Study: NCT03849287
Drug: CKD-333, formula I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug
Study: NCT03849287
Drug: CKD-333, formula II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug
Study: NCT03849287
Drug: CKD-330, D090
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference Drug
Study: NCT01330459
Drug: Hydrocodone/acetaminophen
Normalized name: hydrocodone/acetaminophen 5 mg-500 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 2 tablets 5/325mg hydrocodone/acetaminophen 45-90 minutes prior to procedure.
Study: NCT01330459
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 2 tablets methylcellulose (placebo) 45-90 minutes prior to procedure.
Study: NCT01330459
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg oral ibuprofen
Study: NCT01231399
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01231399
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02483208
Drug: BAY81-8973
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY81-8973 infusion to analyze pharmacokinetics
Study: NCT00650208
Drug: Lamictal® Tablets 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2x25mg, single dose fasting
Study: NCT03204708
Drug: iv analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients were given 100 ml of tramadol 30 minutes before extubation
Study: NCT03657758
Drug: EPA and rosuvastatin
Normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: To take EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for ９ months.
Study: NCT03657758
Drug: High dose rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: To take high dose rosuvastatin (10mg/day) for ９ months.
Study: NCT01759732
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg IV on day-3 and -2
Study: NCT01777620
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.
Study: NCT00714961
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: plus acetylsalicylic acid (ASA)
Study: NCT02936414
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accept placebo(300 mg/tid)+SGAs monotherapy.
Study: NCT00408954
Drug: UK-369,003
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg MR tablet once daily for 2 weeks
Study: NCT00408954
Drug: UK-369,003
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK-369,003-100 mg MR formulation for 2 weeks
Study: NCT00433537
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00433537
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02906761
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 tablets) twice daily for 6 months
Study: NCT03893565
Drug: GSK2831781 - Double Blind Phase
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2831781 will be administered intravenously in the double blind induction phase and subcutaneously in the double blind ETP (both according to randomization).
Study: NCT03893565
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (commercial saline solution) will be administered intravenously in the double blind induction phase and subcutaneously in the double blind ETP (both according to randomization).
Study: NCT00723723
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin
Study: NCT02125253
Drug: Nasonex Nasal Spray, 50 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate monohydrate
Study: NCT02125253
Drug: Placebo Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: a metered-dose, manual pump spray unit containing an aqueous suspension
Study: NCT00128830
Drug: Nucleotide reverse transcriptase inhibitors (NRTIs)
Normalized name: Nucleoside and nucleotide reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
Study: NCT00128830
Drug: Protease inhibitors (PIs)
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
Study: NCT01084174
Drug: Placebo extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delivered sublingually
Study: NCT01084174
Drug: Placebo powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delivered orally
Study: NCT00708162
Drug: EVG placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match elvitegravir administered orally once daily
Study: NCT00708162
Drug: RAL placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAL placebo administered orally twice daily.
Study: NCT04417621
Drug: LTT462
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTT462 will be supplied as hard gelatin capsule for oral use.
Study: NCT00708162
Drug: Background regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Background Regimen (administered according to prescribing information) contains 1 fully-active ritonavir-boosted protease inhibitor (PI/r) plus 1 or 2 additional agents. The ritonavir-boosted PIs include either ATV, darunavir, fosamprenavir, LPV (Kaletra®), or tipranavir; the additional agents include abacavir (ABC), Combivir® (lamivudine (LAM)/zidovudine (ZDV) coformulated), didanosine, emtricitabine (FTC), enfuvirtide, Epzicom® (ABC/LAM coformulated), etravirine, LAM, maraviroc, tenofovir disoproxil fumarate (TDF), Truvada®, (FTC/TDF coformulated), and/or ZDV.
Study: NCT00855179
Drug: Red vine leaf extract (AS 195)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antistax film-coated tablet 360 mg
Study: NCT00855179
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets identical to those containing Anstistax 360 mg
Study: NCT00718913
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be given orally at 1800 mg/m2 days 1 through 14 divided in two daily doses before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Capecitabine at 1800 mg/m2 days 1 through 14 (divided in two daily doses).
Study: NCT00718913
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be administered orally during radiotherapy for radiosensitization(1650 mg/m2 per day divided in two daily doses, 5 days/week, on Monday through Friday).
Study: NCT06105827
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Give antibiotics or diclofenac sodium suppository as needed.
Study: NCT06105827
Drug: Ningmitai capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Ningmitai Capsule (produced by Guiyang Xintian Pharmaceutical Co., Ltd.), 0.38 g/capsule, 4 capsules each time, 3 times a day for 12 Weeks.
Study: NCT06105827
Drug: Combined group (Ningmitai plus tamsulosin)
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin capsules, 0.2 mg/capsule, one capsule each time, once a day, were taken on the basis of Ningmitai group for 12 Weeks.
Study: NCT02658838
Drug: full amount low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
Study: NCT02658838
Drug: half amount low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
Study: NCT02658838
Drug: No low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were treated with no low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
Study: NCT02606539
Drug: Methotrexate plus folinic acid alone
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: methotrxate 1mg/kg every other day alternating with calcium folinate 0.1 mg/kg for 4 doses each cycle then measuring B-HCG and cycle repeated until normalization of B-HCG
Study: NCT02368951
Drug: BAY1187982
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dose of 0.1 mg BAY 1187982 per kilogram (kg) body weight (BW) was chosen as the starting dose based on toxicology data. The investigational drug will be administered as a 1-hour IV infusion once every 21 days at the trial site (Day 1 of each 21-day Cycle). The maximum possible dose escalation will be 2-fold and not more than 0.5 mg/kg BW until maximum tolerated dose is selected
Study: NCT02302547
Drug: triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage treatment and usual prescription
Study: NCT00563576
Drug: Femring®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen vaginal ring (100 mcg) placed for the first 90 days of Depo-Provera use.~Femring® (estradiol acetate vaginal ring) is a flexible off-white ring designed for vaginal insertion with measurements that include an outer diameter of 56 mm, cross-sectional diameter of 7.6 mm, and core diameter of 2 mm. Femring® 0.1 mg/day has a central core containing 24.8 mg of estradiol acetate which releases at a rate equivalent to 0.1 mg of estradiol per day for 3 months.
Study: NCT00563576
Drug: DepoProvera ®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medroxyprogesterone intramuscular injection comes as a suspension (liquid) to be injected into the buttocks or upper arm. It is usually given once every 3 months (13 weeks), and the recommended dose is 150 mg.
Study: NCT01595386
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The drug will be bolused at 50mg/m2 followed by a continuous infusion that will start at 50mg/m2 for the first 48 hours and then be tapered as follows: 40mg/m2/day over 24 hours, 30mg/m2/day over 12 hours, 20 mg/m2/day over 12 hours, 10mg/m2/day over 24 hours, then off.
Study: NCT01595386
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: This will be bolused and infused in the same manner as the hydrocortisone arm to ensure blinding of study arm.
Study: NCT00357084
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00503009
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02761005
Drug: Eradication of H. pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the eradication of H. pylori, patients diagnosed to be infected with strain with mutation of 23S rRNA, their H. pylori strains are considered to be resistant to clarithromycin. Then, they are treated with vonoprazan 40 mg, metronidazole 500 mg and amoxicillin 1500 mg for 1 week. Patients diagnosed to be infected with strain without mutation of 23S rRNA, their H. pylori strains are considered to be resistant to clarithromycin. Then, they are treated with vonoprazan 40 mg, clarithromycin 400 mg and amoxicillin 1500 mg for 1 week.
Study: NCT02952898
Drug: Diclofenac Sodium Gel, 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac sodium gel, 3% is an FDA-approved drug.
Study: NCT02952898
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle topical gel contains 0.0% of active drug and is color matched to the other two active test drugs.
Study: NCT01975727
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of placebo (saline 0.9%)
Study: NCT03444376
Drug: KEYTRUDA®
Approvals — FDA: no, EMA: no, PMDA: no
Description: pembrolizumab(100mg/4mL/vial), Intravenous administration
Study: NCT00801580
Drug: doxorubicin liposomal
Normalized name: DOXOrubicin liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Cyclophosphamide~* Mesna~* Methotrexate~* Doxorubicin liposomal~* Vincristine~* Dexamethasone~* Rituximab~* Cytarabine
Study: NCT02832180
Drug: OC containing EE and NET
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06016036
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAL-0951 placebo：~1. initial phase：4mg QD for 8 weeks~2. subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
Study: NCT01160172
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intramuscular vaccination according to protocol schedule
Study: NCT01879930
Drug: doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zadorin-100® (doxycycline), licence number Swissmedic: 43051 Legal holder: Mepha Pharma AG, Aesch/BL~Oral intake during study period (4 weeks) once in the morning and once in the evening~The masking of the agents is conducted using bordeaux-coloured, opaque hard-gelatine capsules (size 00) of the French company LGA. The hard-gelatine capsules are each filled with 1 unit Zadorin® 100
Study: NCT04885153
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were given simvastatin 10 mg and placebo (lactic acid) 200 mg daily for three months and were evaluated monthly.
Study: NCT04365218
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution for injection and the placebo volume to be administered will be equivalent to the MEDI8367 volume administered for each dosing cohort.
Study: NCT00721630
Drug: capecitabine, lapatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine 2,000mg twice daily for 7 days followed by a 7-day rest in combination with lapatinib 1,250mg orally daily. Cycle length is 28 days (+/- 2 days).Toxicity assessment will occur q2 weeks for the first 4 weeks, then q4 weeks(+/- 2 days). Radiographic response assessment will take place q12 weeks (+/- 1 week). LVEF assessment will be repeated q12 weeks (+/- 1 week).
Study: NCT00792935
Drug: MK-0941
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0941 will be taken three times a day (TID), within 15 minutes before each meal. MK-0941 will be titrated to a maximally effective dose. The treatment period will be 6 weeks.
Study: NCT03925714
Drug: Nigetella salivata
Normalized name: Nigella sativa seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: NS twice daily
Study: NCT04260555
Drug: DW1601
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total 7 days of treatment and The daily dose is tid. (DW1601 20ml + Placebo of DW16011 20ml + Placebo of DW16012 9ml)
Study: NCT04260555
Drug: DW16011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total 7 days of treatment and The daily dose is tid. (Placebo of DW1601 20ml + DW16011 20ml + Placebo of DW16012 9ml)
Study: NCT04260555
Drug: DW16012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total 7 days of treatment and The daily dose is tid. (Placebo of DW1601 20ml + Placebo of DW16011 20ml + DW16012 9ml)
Study: NCT02183181
Drug: Meloxicam capsule
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02183181
Drug: Meloxicam tablet
Normalized name: Meloxicam Tablets
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02155543
Drug: AGN-223575 Formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop of AGN-223575 Formulation B in both eyes on day 1, followed by one drop of AGN-223575 Formulation B twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation B in both eyes on day 15.
Study: NCT02155543
Drug: AGN-223575 Vehicle
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop of AGN-223575 vehicle administered in the study eye(s) per protocol.
Study: NCT03665441
Drug: Irinotecan plus 5-FU plus leucovorin
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: irinotecan, 5-FU, leucovorin
Study: NCT05783830
Drug: ACD856
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV injection 100 mcg
Study: NCT04443348
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Starting Week 15 and administered every 2 weeks for 4 cycles (up to 4 doses) into your vein (by intravenous infusion).
Study: NCT04443348
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting Week 15 and administered every 2 weeks for 4 cycles (up to 4 doses) into your vein (by intravenous infusion). Doxorubicin will be administered after pembrolizumab.
Study: NCT04443348
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine after surgery is optional for TNBC patients and should be discussed with the study doctor.~Starting 3-6 weeks after surgery, administered orally twice daily for 6 courses, each 3 weeks long (for a total of 18 weeks).
Study: NCT00616798
Drug: RO4917838
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg po daily
Study: NCT00616798
Drug: RO4917838
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg po daily
Study: NCT00616798
Drug: RO4917838
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60mg po daily
Study: NCT00616798
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po daily
Study: NCT00616798
Drug: Standard antipsychotic therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed
Study: NCT00871273
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: film-coated tablet 1250 mg/m2 twice daily 14 days for 14 days. Number of cycles: 3 cycles pre-operatively and 3 cycles post-operatively unless there is evidence of disease progression on chemotherapy
Study: NCT01206101
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation escalation of liraglutide up to 1.2 to 1.8 mg before islet cell transplant until the planned number of transplanted subjects is complete or subject is transplanted. After islet cell transplant, subjects continue to receive the reached liraglutide placebo dose for 52 weeks. Injected subcutaneously (under the skin) once daily.
Study: NCT01258712
Drug: Tocilizumab + methotrexate(MTX)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab:8 mg/kg every4weeks,IV infusion methotrexate:10-20 mg/week
Study: NCT00027248
Drug: MBI 226
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02475837
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will match the study drug, vorapaxar sulfate, in appearance. A 12-week supply will be dispensed to enrolled patients on the first day following surgery.
Study: NCT00152724
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00152724
Drug: indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00152724
Drug: acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00152724
Drug: brethyllium
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01009697
Drug: Codeine Sulfate
Normalized name: Codeine Sulfate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 mg, 30 mg, and 60 mg tablets
Study: NCT02538848
Drug: HTD4010
Approvals — FDA: no, EMA: no, PMDA: no
Description: injectable solution
Study: NCT04364425
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided injection using 15ml or 12 ml of normal saline